Real life experiences in HCV management in 2018

Mauro Viganò, Massimo Andreoni, Carlo Federico Perno, Antonio Craxì, Alessio Aghemo, Alfredo Alberti, Pietro Andreone, Sergio Babudieri, Stefano Bonora, Maurizia Rossana Brunetto, Raffaele Bruno, Savino Bruno, Vincenza Calvaruso, Nicola Caporaso, Fabio Cartabellotta, Francesca Ceccherini-Silberstein, Valeria Cento, Alessia Ciancio, Piero Colombatto, Nicola CoppolaVito Di Marco, Giovanni Di Perri, Stefano Fagiuoli, Giovanni Battista Gaeta, Antonio Gasbarrini, Pietro Lampertico, Adriano Pellicelli, Tullio Prestileo, M Puoti, G Raimondo, Giuliano Rizzardini, Gloria Taliani, Anna Linda Zignego

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient's identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.

Original languageEnglish
JournalExpert Review of Anti-Infective Therapy
DOIs
Publication statusE-pub ahead of print - Dec 24 2018

Fingerprint

Life Change Events
Hepacivirus
Liver Diseases
Antiviral Agents
Therapeutics
Liver
Chronic Hepatitis C
Virus Diseases
Health Status
Disease Progression
Chronic Disease
Mortality

Cite this

Viganò, M., Andreoni, M., Perno, C. F., Craxì, A., Aghemo, A., Alberti, A., ... Zignego, A. L. (2018). Real life experiences in HCV management in 2018. Expert Review of Anti-Infective Therapy. https://doi.org/10.1080/14787210.2019.1563755

Real life experiences in HCV management in 2018. / Viganò, Mauro; Andreoni, Massimo; Perno, Carlo Federico; Craxì, Antonio; Aghemo, Alessio; Alberti, Alfredo; Andreone, Pietro; Babudieri, Sergio; Bonora, Stefano; Brunetto, Maurizia Rossana; Bruno, Raffaele; Bruno, Savino; Calvaruso, Vincenza; Caporaso, Nicola; Cartabellotta, Fabio; Ceccherini-Silberstein, Francesca; Cento, Valeria; Ciancio, Alessia; Colombatto, Piero; Coppola, Nicola; Di Marco, Vito; Di Perri, Giovanni; Fagiuoli, Stefano; Gaeta, Giovanni Battista; Gasbarrini, Antonio; Lampertico, Pietro; Pellicelli, Adriano; Prestileo, Tullio; Puoti, M; Raimondo, G; Rizzardini, Giuliano; Taliani, Gloria; Zignego, Anna Linda.

In: Expert Review of Anti-Infective Therapy, 24.12.2018.

Research output: Contribution to journalArticle

Viganò, M, Andreoni, M, Perno, CF, Craxì, A, Aghemo, A, Alberti, A, Andreone, P, Babudieri, S, Bonora, S, Brunetto, MR, Bruno, R, Bruno, S, Calvaruso, V, Caporaso, N, Cartabellotta, F, Ceccherini-Silberstein, F, Cento, V, Ciancio, A, Colombatto, P, Coppola, N, Di Marco, V, Di Perri, G, Fagiuoli, S, Gaeta, GB, Gasbarrini, A, Lampertico, P, Pellicelli, A, Prestileo, T, Puoti, M, Raimondo, G, Rizzardini, G, Taliani, G & Zignego, AL 2018, 'Real life experiences in HCV management in 2018', Expert Review of Anti-Infective Therapy. https://doi.org/10.1080/14787210.2019.1563755
Viganò, Mauro ; Andreoni, Massimo ; Perno, Carlo Federico ; Craxì, Antonio ; Aghemo, Alessio ; Alberti, Alfredo ; Andreone, Pietro ; Babudieri, Sergio ; Bonora, Stefano ; Brunetto, Maurizia Rossana ; Bruno, Raffaele ; Bruno, Savino ; Calvaruso, Vincenza ; Caporaso, Nicola ; Cartabellotta, Fabio ; Ceccherini-Silberstein, Francesca ; Cento, Valeria ; Ciancio, Alessia ; Colombatto, Piero ; Coppola, Nicola ; Di Marco, Vito ; Di Perri, Giovanni ; Fagiuoli, Stefano ; Gaeta, Giovanni Battista ; Gasbarrini, Antonio ; Lampertico, Pietro ; Pellicelli, Adriano ; Prestileo, Tullio ; Puoti, M ; Raimondo, G ; Rizzardini, Giuliano ; Taliani, Gloria ; Zignego, Anna Linda. / Real life experiences in HCV management in 2018. In: Expert Review of Anti-Infective Therapy. 2018.
@article{89b024cd01ea4e9698c59fc406bfd04b,
title = "Real life experiences in HCV management in 2018",
abstract = "INTRODUCTION: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct acting antivirals able to achieve sustained virological response in more than 95{\%} of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient's identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.",
author = "Mauro Vigan{\`o} and Massimo Andreoni and Perno, {Carlo Federico} and Antonio Crax{\`i} and Alessio Aghemo and Alfredo Alberti and Pietro Andreone and Sergio Babudieri and Stefano Bonora and Brunetto, {Maurizia Rossana} and Raffaele Bruno and Savino Bruno and Vincenza Calvaruso and Nicola Caporaso and Fabio Cartabellotta and Francesca Ceccherini-Silberstein and Valeria Cento and Alessia Ciancio and Piero Colombatto and Nicola Coppola and {Di Marco}, Vito and {Di Perri}, Giovanni and Stefano Fagiuoli and Gaeta, {Giovanni Battista} and Antonio Gasbarrini and Pietro Lampertico and Adriano Pellicelli and Tullio Prestileo and M Puoti and G Raimondo and Giuliano Rizzardini and Gloria Taliani and Zignego, {Anna Linda}",
year = "2018",
month = "12",
day = "24",
doi = "10.1080/14787210.2019.1563755",
language = "English",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Real life experiences in HCV management in 2018

AU - Viganò, Mauro

AU - Andreoni, Massimo

AU - Perno, Carlo Federico

AU - Craxì, Antonio

AU - Aghemo, Alessio

AU - Alberti, Alfredo

AU - Andreone, Pietro

AU - Babudieri, Sergio

AU - Bonora, Stefano

AU - Brunetto, Maurizia Rossana

AU - Bruno, Raffaele

AU - Bruno, Savino

AU - Calvaruso, Vincenza

AU - Caporaso, Nicola

AU - Cartabellotta, Fabio

AU - Ceccherini-Silberstein, Francesca

AU - Cento, Valeria

AU - Ciancio, Alessia

AU - Colombatto, Piero

AU - Coppola, Nicola

AU - Di Marco, Vito

AU - Di Perri, Giovanni

AU - Fagiuoli, Stefano

AU - Gaeta, Giovanni Battista

AU - Gasbarrini, Antonio

AU - Lampertico, Pietro

AU - Pellicelli, Adriano

AU - Prestileo, Tullio

AU - Puoti, M

AU - Raimondo, G

AU - Rizzardini, Giuliano

AU - Taliani, Gloria

AU - Zignego, Anna Linda

PY - 2018/12/24

Y1 - 2018/12/24

N2 - INTRODUCTION: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient's identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.

AB - INTRODUCTION: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient's identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.

U2 - 10.1080/14787210.2019.1563755

DO - 10.1080/14787210.2019.1563755

M3 - Article

C2 - 30582384

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

ER -